Managing patients with non-small cell lung cancer (NSCLC) across the disease continuum is a complex task.

Join Jeffrey Bradley, MD (Radiation Oncology), Ramaswamy Govindan, MD (Medical Oncology), and Peter Humphrey, MD, PhD (Surgical Pathology) as they present their multidisciplinary expertise on a range of cases pertaining to advanced adenocarcinoma.

These NCCN Guidelines Insights focus on the diagnostic evaluation of suspected lung cancer. This topic was a major update for the 2013 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC).

Leptomeningeal carcinomatosis (LM) is an infrequent, yet morbid and often fatal complication of non–small cell lung cancer (NSCLC).

For many years, small cell lung cancer (SCLC) has been staged using the Veterans Affairs classification system, which includes only 2 stages: limited (primary tumor and regional lymph nodes within a tolerable radiation field) and extensive (anything beyond limited stage).

The Westin Diplomat
Hollywood, Florida

Lung cancer remains the deadliest cancer, with more than 159,000 deaths and 220,000 newly diagnosed cases in 2011. Because treatment and survival are directly linked to disease stage, accurate staging in all patients is crucial.

This archived educational webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Non-Small Cell Lung Cancer and Small Cell Lung Cancer.

This archived educational webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Non-Small Cell Lung Cancer and Small Cell Lung Cancer (SCLC).

This archived educational webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer.